Ogasawara Hayato | Pharmacology Division National Cancer Center Research Institute
スポンサーリンク
概要
関連著者
-
Saijo N
Division Of Internal Medicine National Cancer Center Hospital East
-
Saijo Nagahiro
国立医薬品食品衛生研究所
-
Saijo N
Medical Oncology National Cancer Center Hospital
-
Nishio K
Department Of Genome Biology Kinki University School Of Medicine
-
Kuzuya Nobuaki
国立医薬食品衛生研究所 薬物応答予測プロジェクト
-
NISHIO Kazuto
Pharmacology Division, National Cancer Center Research Institute
-
Saijo Nagahiro
Pharmacology Division, National Cancer Center Research Institute
-
Ogasawara H
Pharmacology Division National Cancer Center Research Institute
-
Ogasawara Hayato
国立がんセンター
-
Ogasawara Hayato
Pharmacology Division National Cancer Center Research Institute
-
Nishio Kazuto
Pharmacology Division National Cancer Center Research Institute
-
Saijo Nagahiro
Pharmacology Division National Cancer Center Research Institute
-
OGASAWARA Hayato
Pharmacology Division, National Cancer Center Research Institute
-
Kanzawa Fumihiko
国立がんセンター
-
Kanzawa Fumihiko
Pharmacology:pathology Division National Cancer Center Research Institute:surgery Division:departmen
-
Fukuoka K
National Cancer Center Res. Inst.
-
Kaniwa N
Department Of Genome Biology Kinki University School Of Medicine
-
NISHIO Kazuto
Department of Genome Biology, Kinki University School of Medicine
-
ARIOKA Hitoshi
Pharmacology Division, National Cancer Center Research Institute
-
ISHIDA Tomoyuki
Pharmacology Division, National Cancer Center Research Institute
-
FUKUOKA Kazuya
Pharmacology Division, National Cancer Center Research Institute
-
FUKUDA Minoru
Department of Medical Oncology, National Cancer Center Hospital
-
Bojanowski Okrzystof
Institut Gustave Roussy, Laboratoire de Biochimie et de Physicochimie Macromoleculaire CNRS URA
-
Fukuda Minoru
Pharmacology Divisionof National Cancer center Reserch Institute
-
Larsen Annette
Institut Gustave Roussy, Laboratoire de Biochimie et de Physicochimie Macromoleculaire CNRS URA
-
Kanzawa Fumihiko
Pharmacology Division National Cancer Center Research Institute
-
Ishida Tomoyuki
Pharmacology Division National Cancer Center Research Institute
-
Ishida Tomoyuki
国立がんセンター
-
Bojanowski Okrzystof
Institut Gustave Roussy Laboratoire De Biochimie Et De Physicochimie Macromoleculaire Cnrs Ura:pharm
-
Arioka H
National Cancer Center Res. Inst.
-
Arioka Hiroshi
国立がんセンター
-
Arioka Hitoshi
国立がんセンター中央病院
-
Arioka Hitoshi
Pharmacology Division National Cancer Center Research Institute
-
Larsen Annette
Institut Gustave Roussy Laboratoire De Biochimie Et De Physicochimie Macromoleculaire Cnrs Ura:pharm
-
Saijo Nagahiro
Department Of Internal Medicine National Cancer Center Hospital
-
LEE Yong-Sik
Pharmacology Division, National Cancer Center Research Institute
-
FUNAYAMA Yasunori
Pharmacology Division, National Cancer Center Research Institute
-
OHIRA Tatsuo
Pharmacology Division, National Cancer Center Research Institute
-
KURAISHI Yasunobu
The Third Department of Internal Medicine, Jikei University School of Medicine
-
ISOGAI Yukihide
The Third Department of Internal Medicine, Jikei University School of Medicine
-
Isogai Yukihide
The Third Department Of Internal Medicine Jikei University School Of Medicine
-
Fukuda Minoru
Department Of Medical Oncology National Cancer Center Hospital
-
Ohira Tatsuo
Pharmacology Division National Cancer Canter Research Institute
-
Funayama Yasunori
Pharmacology Division National Cancer Center Research Institute
-
Lee Yong-sik
Pharmacology Division National Cancer Center Research Institute
-
Ohira Tatsuo
Pharmacology Division National Cancer Center Research Institute
-
Kuraishi Yasunobu
The Third Department Of Internal Medicine Jikei University School Of Medicine
-
Fukuoka Kazuya
Pharmacology Division National Cancer Center Research Institute
著作論文
- In vitro Enhancement of Antitumor Activity of a Water-soluble Duocarmycin Derivative, KW-2189, by Caffeine-mediated DNA-repair Inhibition in Human Lung Cancer Cells
- Effect of suramin on cdc2 kinase activity of the purified enzyme and from the crude extracts from lung cancer cells
- Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW-2189 in Cell Lines Resistant to Cisplatin and CPT-11